Apathy, one of the most common neuropsychiatric symptoms in Parkinson’s disease (PD), has been associated with reduced daily functioning, cognition, treatment compliance, quality of life, and increased caregiver burden and distress, among other outcomes.
Objectives:
The purpose of the present study was to develop and gather pilot data on the feasibility, acceptability, and efficacy of the Parkinson’s Active Living (PAL) program, to our knowledge, the first behavioral treatment specifically designed to target apathy in patients with PD. The Parkinson’s Active Living is a primarily telephone-based, 6-week activity scheduling and monitoring intervention that incorporates external cueing to target disease-related self-generational deficits to reduce levels of apathy in nondemented, highly apathetic patients with PD.
Methods:
Participants aged 44 to 86 years (mean = 66, SD [standard deviation] = 10.7) ranging in disease duration from <1 to 23 years with elevated apathy (Apathy Evaluation Scale >35) were enrolled in a 1-arm trial and tested at 3 time points (baseline, posttest, and 1-month follow-up).
Results:
Feasibility aspects (ie, acceptability, demand, implementation, practicality, adaptation, integration, and expansion) and efficacy of PAL program are reported. Matched pairs t tests showed a medium to large effect of treatment on patient apathy (52% showing ≥1 SD improvement), depression (33% showing ≥1 SD improvement), and quality of life at posttest, with improvements in apathy and depression maintained at follow-up.
Conclusions:
The program may hold promise as an effective nonpharmacological intervention for apathy in PD. Implications and future directions are discussed. Randomized controlled trials are needed.
den BrokMGvan DalenJWvan GoolWAMoll van CharanteEPde BieRRichardE. Apathy in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2015;30(6):759–769.
2.
OnyikeCUSheppardJMTschanzJT. Epidemiology of apathy in older adults: the Cache County Study. Am J Geriatr Psychiatry. 2007;15(5):365–375.
3.
De VugtMEStevensFAaltenP. Behavioural disturbances in dementia patients and quality of the marital relationship. Int J Geriatr Psychiatry. 2003;18(2):149–154.
4.
YeagerCAHyerL. Apathy in dementia: relations with depression, functional competence, and quality of life. Psychol Rep. 2008;102(3):718–722.
5.
IsellaVMelziPGrimaldiM. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson’s disease. Mov Disord. 2002;17(2):366–371.
6.
PluckGCBrownRG. Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73(6):636–642.
7.
FeilDRazaniJBooneKLesserI. Apathy and cognitive performance in older adults with depression. Int J Geriatr Psychiatry. 2003;18(6):479–485.
8.
ZahodneLBTremontG. Unique effects of apathy and depression signs on cognition and function in amnestic mild cognitive impairment. Int J Geriatr Psychiatry. 2013;28(1):50–56.
9.
SommeJFernández-MartínezMMolanoAJose ZarranzJ. Neuropsychiatric symptoms in amnestic mild cognitive impairment: increased risk and faster progression to dementia. Curr Alzheimer Res. 2013;10(1):86–94.
10.
RichardESchmandBEikelenboomP; Alzheimer’s Disease Neuroimaging Initiative. Symptoms of apathy are associated with progression from mild cognitive impairment to Alzheimer’s disease in non-depressed subjects. Dement Geriatr Cogn Disord. 2012;33(2-3):204–209.
11.
DoodyRSMassmanPMahurinRLawS. Positive and negative neuropsychiatric features in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 1995;7(1):54–60.
StarksteinSJorgeRMizrahiRRobinsonRG. A prospective longitudinal study of apathy in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2006;77(1):8–11.
14.
Van der MusseleSFransenEStruyfsH. Depression in mild cognitive impairment is associated with progression to Alzheimer’s disease: a longitudinal study. J Alzheimers Dis. 2014;42(4):1239–1250.
Groeneweg-KoolhovenIde WaalMWvan der WeeleGMGusseklooJvan der MastRC. Quality of life in community-dwelling older persons with apathy. Am J Geriatr Psychiatry. 2014;22(2):186–194.
17.
NortonLEMalloyPFSallowayS. The impact of behavioral symptoms on activities of daily living in patients with dementia. Am J Geriatr Psychiatry. 2002;9(1):41–48.
18.
SamusQMRosenblattASteeleC. The association of neuropsychiatric symptoms and environment with quality of life in assisted living residents with dementia. Gerontologist. 2005;45(suppl 1):19–26.
19.
VelliganDIRitchJLSuiDDiCoccoMHuntzingerCD. Frontal Systems Behavior Scale in schizophrenia: relationships with psychiatric symptomatology, cognition and adaptive function. Psychiatry Res. 2002;113(3):227–236.
20.
ResnickBZimmermanSIMagazinerJAdelmanA. Use of the Apathy Evaluation Scale as a measure of motivation in elderly people. Rehabil Nurs. 1998;23(3):141–147.
21.
CattelaniRRobertiRLombardiF. Adverse effects of apathy and neurobehavioral deficits on the community integration of traumatic brain injury subjects. Eur J Phys Rehabil Med. 2008;44(3):245–251.
22.
MayoNEFellowsLKScottSCCameronJWood-DauphineeS. A longitudinal view of apathy and its impact after stroke. Stroke. 2009;40(10):3299–3307.
23.
KauferDICummingsJLChristineD. Assessing the impact of neuropsychiatric symptoms in Alzheimer’s disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998;46(2):210–215.
AarslandDBrønnickKEhrtU. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007;78(1):36–42.
26.
StarksteinSEMaybergHSPreziosiTJAndrezejewskiPLeiguardaRRobinsonRG. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1992;4(2):134–139.
27.
ButterfieldLCCiminoCROelkeLEHauserRASanchez-RamosJ. The independent influence of apathy and depression on cognitive functioning in Parkinson’s disease. Neuropsychology. 2010;24(6):721–730.
28.
VaraneseSPerfettiBGhilardiMFDi RoccoA. Apathy, but not depression, reflects inefficient cognitive strategies in Parkinson’s disease. PLoS One. 2011;6(3): e17846.
29.
NgAChanderRJTanLCKandiahN. Influence of depression in mild Parkinson’s disease on longitudinal motor and cognitive function. Parkinsonism Relat Disord. 2015;21(9):1056–1060.
30.
CostaAPeppeACarlesimoGAPasqualettiPCaltagironeC. Major and minor depression in Parkinson’s disease: a neuropsychological investigation. Eur J Neurol. 2006;13(9):972–980.
31.
Kirsch-DarrowLFernandezHHMarsiskeMOkunMBowersD. Dissociating apathy and depression in Parkinson disease. Neurology. 2006;67(1):33–38.
32.
OguruMTachibanaHTodaKOkudaBOkaN. Apathy and depression in Parkinson disease. J Geriatr Psychiatry Neurol. 2010;23(1):35–41.
33.
WeintraubDMobergPJDudaJEKatzIRSternMB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J Am Geriatr Soc. 2004;52(5):784–788.
34.
LaatuSKarraschMMartikainenKMarttilaR. Apathy is associated with activities of daily living ability in Parkinson’s disease. Dement Geriatr Cogn Disord. 2013;35(5-6):249–255.
35.
Benito-LeónJCuboECoronellC; ANIMO Study Group. Impact of apathy on health-related quality of life in recently diagnosed Parkinson’s disease: the ANIMO study. Mov Disord. 2012;27(2):211–218.
36.
BrodatyHBurnsK. Nonpharmacological management of apathy in dementia: a systematic review. Am J Geriatr Psychiatry. 2012;20(7):549–564.
37.
TroeungLEganSJGassonN. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson’s disease. PLoS One. 2013;8(11): e79510.
38.
CuijpersPSijbrandijMKooleSLAnderssonGBeekmanATReynoldsCFIII. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry. 2014;13(1):56–67.
39.
PampallonaSBolliniPTibaldiGKupelnickBMunizzaC. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry. 2004;61(7):714–719.
40.
RothRMFlashmanLAMcAllisterTW. Apathy and its treatment. Curr Treat Options Neurol. 2007;9(5):363–370.
41.
ZgaljardicDJBorodJCFoldiNS. Relationship between self-reported apathy and executive dysfunction in nondemented patients with Parkinson disease. Cogn Behav Neurol. 2007;20(3):184–192.
42.
van ReekumRStussDTOstranderL. Apathy: why care?J Neuropsychiatry Clin Neurosci. 2005;17(1):7–19.
43.
LewinsohnP. The behavioral study and treatment of depression. In: HersenMEislerRMMillerPM, eds. Progress in Behaviour Modification. New York, NY: Academic Press; 1975; 1:19–64.
44.
LejuezCWHopkoDRHopkoSD. A brief behavioral activation treatment for depression treatment manual. Behav Modif. 2001;25(2):255–286.
45.
LathamGPLockeEA. Self-regulation through goal setting. Organ Behav Hum Decis Process. 1991;50(2):212–247.
46.
LockeEALathamGP. Building a practically useful theory of goal setting and task motivation: a 35-year odyssey. Am Psychol. 2002;57(9):705–717.
47.
BanduraA. Self-regulation of motivation through anticipatory and self-reactive mechanisms. In: DienstbierRA, ed. Perspectives on Motivation: Nebraska Symposium on Motivation. Vol 38. Lincoln, NE: University of Nebraska Press; 1991:69–164.
48.
BanduraACervoneD. Self-evaluative and self-efficacy mechanisms governing the motivational effects of goal systems. J Pers Soc Psychol. 1983;45(5):1017–1028.
49.
GollwitzerPMSheeranP. Implementation intentions and goal achievement: a meta-analysis of effects and processes. Adv Exp Soc Psychol. 2006;38:69–119.
50.
FrankenRE. Human Motivation. 6th ed. Portland, OR: Wadsworth Publishing; 2007.
51.
KranickSMHallettM. Neurology of volition. Exp Brain Res. 2013;229(3):313–327.
52.
KrieghoffVWaszakFPrinzWBrassM. Neural and behavioral correlates of intentional actions. Neuropsychologia. 2011;49(5):767–776.
53.
LewisGNByblowWDWaltSE. Stride length regulation in Parkinson’s disease: the use of extrinsic, visual cues. Brain. 2000;123(10):2077–2090.
54.
SuteerawattananonMMorrisGSEtnyreBRJankovicJProtasEJ. Effects of visual and auditory cues on gait in individuals with Parkinson’s disease. J Neurol Sci. 2004;219(1):63–69.
55.
GriffinHJGreenlawRLimousinPBhatiaKQuinnNPJahanshahiM. The effect of real and virtual visual cues on walking in Parkinson’s disease. J Neurol. 2011;258(6):991–1000.
56.
BadarnySAharon-PeretzJSuselZHabibGBaramY. Virtual reality feedback cues for improvement of gait in patients with Parkinson’s disease. Tremor Other Hyperkinet Mov(N Y). 2014;4:225.
57.
HoweTELövgreenBCodyFWAshtonVJOldhamJA. Auditory cues can modify the gait of persons with early-stage Parkinson’s disease: a method for enhancing parkinsonian walking performance?Clin Rehabil. 2003;17(4):363–367.
58.
BellaSDBenoitCEFarrugiaNSchwartzeMKotzSA. Effects of musically cued gait training in Parkinson’s disease: beyond a motor benefit. Ann N Y Acad Sci. 2015;1337(1):77–85.
59.
Burleigh-JacobsAHorakFBNuttJGObesoJA. Step initiation in Parkinson’s disease: influence of levodopa and external sensory triggers. Mov Disord. 1997;12(2):206–215.
60.
SpauldingSJBarberBColbyMCormackBMickTJenkinsME. Cueing and gait improvement among people with Parkinson’s disease: a meta-analysis. Arch Phys Med Rehabil. 2013;94(3):562–570.
61.
WeiermannBStephanMAKaelin-LangAMeierB. Is there a recognition memory deficit in Parkinson’s disease? Evidence from estimates of recollection and familiarity. Int J Neurosci. 2010;120(3):211–216.
62.
CostaAMonacoMZabberoniS. Free and cued recall memory in Parkinson’s disease associated with amnestic mild cognitive impairment. PLoS One. 2014;9(1): e86233.
63.
WerheidKKochIReichertKBrassM. Impaired self-initiated task preparation during task switching in Parkinson’s disease. Neuropsychologia. 2007;45(2):273–281.
64.
BarrettAMCrucianGPSchwartzRLHeilmanKM. Testing memory for self-generated items in dementia method makes a difference. Neurology. 2000;54(6):1258–1264.
65.
DobkinRDRubinoJTFriedmanJAllenLAGaraMAMenzaM. Barriers to mental health care utilization in Parkinson’s disease. J Geriatr Psychiatry Neurol. 2013;26(2):105–116.
66.
SimonGELudmanEJTuttySOperskalskiBVon KorffM. Telephone psychotherapy and telephone care management for primary care patients starting antidepressant treatment: a randomized controlled trial. JAMA. 2004;292(8):935–942.
67.
ChaudhuriKRMartinez-MartinPSchapiraAH. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord. 2006;21(7):916–923.
68.
LehrnerJMoserDKlugS. Subjective memory complaints, depressive symptoms and cognition in Parkinson’s disease patients. Eur J Neurol. 2014;21(10):1276–1284.
69.
ChiaravallotiNDIbarretxe-BilbaoNDeLucaJ. The source of the memory impairment in Parkinson’s disease: acquisition versus retrieval. Mov Disord. 2014;29(6):765–771.
FolsteinMFFolsteinSEMcHughPR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198.
72.
SpreenOStraussE. Controlled oral word association (word fluency). In: SpreenOStraussE, eds. Compendium of Neuropsychological Tests. Oxford, UK: Oxford University Press; 1991:219–227.
73.
SockeelPDujardinKDevosDDeneveCDestéeADefebvreL. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2006;77(5):579–584.
74.
LarsenDLAttkissonCCHargreavesWANguyenTD. Assessment of client/patient satisfaction: development of a general scale. Eval Program Plann. 1979;2(3):197–207.
75.
AttkissonCCGreenfieldTK. The client satisfaction questionnaire (CSQ) scales: a history of scale development and a guide for users. San Francisco, CA: University of California, Dept. of Psychiatry; 2009.
76.
MarinRS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3(3):243–254.
77.
YesavageJABrinkTLRoseTL. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1983;17(1):37–49.
78.
FahnSEltonRL. Members of the UPDRS Development Committee. Unified Parksinson’s Disease Rating Scale. In: FahnSMarsdenCCalneDGoldsteinM, eds. Recent Developments in Parkinson’s Disease. Florham Park, NJ: Macmillan; 1987; 2:293–304.
79.
PetoVJenkinsonCFitzpatrickRGreenhallR. The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res. 1995;4(3):241–248.
80.
ZaritSHReeverKEBach-PetersonJ. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980;20(6):649–655.
81.
BowenDJKreuterMSpringB. How we design feasibility studies. Am J Prev Med. 2009;36(5):452–457.
MarinRSBiedrzyckiRCFirinciogullariS. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 1991;38(2):143–162.
84.
AdamsKB. Depressive symptoms, depletion, or developmental change? Withdrawal, apathy, and lack of vigor in the Geriatric Depression Scale. Gerontologist. 2001;41(6):768–777.
85.
CressMEBuchnerDMProhaskaT. Best practices for physical activity programs and behavior counseling in older adult populations. J Aging Phys Act. 2005;13(1):61–74.
86.
EakinEGLawlerSPVandelanotteCOwenN. Telephone interventions for physical activity and dietary behavior change: a systematic review. Am J Prev Med. 2007;32(5):419–434.
87.
SaccoWPMorrisonADMaloneJI. A brief, regular, proactive telephone “coaching” intervention for diabetes: rationale, description, and preliminary results. J Diabetes Complications. 2004;18(2):113–118.
88.
SaccoWPMaloneJIMorrisonADFriedmanAWellsK. Effect of a brief, regular telephone intervention by paraprofessionals for type 2 diabetes. J Behav Med. 2009;32(4):349–359.
89.
McBrideCMRimerBK. Using the telephone to improve health behavior and health service delivery. Patient Educ Couns. 1999;37(1):3–18.
90.
PickeringRMFittonCBallingerCFazakarleyLAshburnA. Self reported adherence to a home-based exercise programme among people with Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(1):66–71.
91.
RavenekMJSchneiderMA. Social support for physical activity and perceptions of control in early Parkinson’s disease. Disabil Rehabil. 2009;31(23):1925–1936.
92.
LambertMJBarleyDE. Research summary on the therapeutic relationship and psychotherapy outcome. Psychother Theor Res2001;38(4):357.
93.
LockeEALathamGP. A Theory of Goal Setting & Task Performance. Englewood Cliffs, NJ: Prentice-Hall, Inc; 1990.
94.
ChristensenAJacobsonNS. Who (or what) can do psychotherapy: the status and challenge of nonprofessional therapies. Psychol Sci. 1994;5(1):8–14.
95.
DobkinRDAllenLAMenzaM. Cognitive-behavioral therapy for depression in Parkinson’s disease: a pilot study. Mov Disord. 2007;22(7):946–952.
96.
DobkinRDMenzaMAllenLA. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am J Psychiatry. 2011;168(10):1066–1074.
97.
DobkinRDTrösterAIRubinoJT. Neuropsychological outcomes after psychosocial intervention for depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2014;26(1):57–63.
98.
DobkinRDMenzaMAllenLA. Telephone-based cognitive–behavioral therapy for depression in Parkinson disease. J Geriatr Psychiatry Neurol. 2011;24(4):206–214.
99.
PolitisAMVozzellaSMayerLSOnyikeCUBakerASLyketsosCG. A randomized, controlled, clinical trial of activity therapy for apathy in patients with dementia residing in long-term care. Int J Geriatr Psychiatry. 2004;19(11):1087–1094.
100.
NiuYXTanJPGuanJQZhangZQWangLN. Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer’s disease: a randomized controlled trial. Clin Rehabil. 2010;24(12):1102–1111.
101.
CostafredaSGFuCHLeeLEverittBBrammerMJDavidAS. A systematic review and quantitative appraisal of fMRI studies of verbal fluency: role of the left inferior frontal gyrus. Hum Brain Mapp. 2006;27(10):799–810.
102.
HirshornEAThompson-SchillSL. Role of the left inferior frontal gyrus in covert word retrieval: neural correlates of switching during verbal fluency. Neuropsychologia. 2006;44(12):2547–2557.
103.
SchlösserRHutchinsonMJosefferS. Functional magnetic resonance imaging of human brain activity in a verbal fluency task. J Neurol Neurosurg Psychiatry. 1998;64(4):492–498.
104.
EllfolkUJoutsaJRinneJOParkkolaRJokinenPKarraschM. Striatal volume is related to phonemic verbal fluency but not to semantic or alternating verbal fluency in early Parkinson’s disease. J Neural Transm. 2014;121(1):33–40.
105.
DobkinRDRubinoJTAllenLA. Predictors of treatment response to cognitive-behavioral therapy for depression in Parkinson’s disease. J Consult Clin Psychol. 2012;80(4):694–699.
106.
NorcrossJCKrebsPMProchaskaJO. Stages of change. J Clin Psychol. 2011;67(2):143–154.
107.
MillerWRollnickS. Motivational Interviewing: Preparing People to Change Addictive Behavior. New York, NY: Guillford Press; 1991.
108.
VerheyFRDe VugtMEAaltenPVernooij-DassenMJByrneEJRobertP. Caregiver outcomes in disease modifying trials. J Nutr Health Aging. 2007;11(4):342.
109.
ConstantinescuGTheodorosDRussellTWardEWilsonSWoottonR. Treating disordered speech and voice in Parkinson’s disease online: a randomized controlled non-inferiority trial. Int J Lang Commun Disord. 2011;46(1):1–16.
110.
AnderssonG. Using the Internet to provide cognitive behaviour therapy. Behav Res Ther. 2009;47(3):175–180.
111.
AnderssonGPaxlingBWiweM. Therapeutic alliance in guided internet-delivered cognitive behavioural treatment of depression, generalized anxiety disorder and social anxiety disorder. Behav Res Ther. 2012;50(9):544–550.
112.
FratiglioniLPaillard-BorgSWinbladB. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol. 2004;3(6):343–353.
113.
VergheseJLiptonRBKatzMJ. Leisure activities and the risk of dementia in the elderly. N Engl J Med. 2003;348(25):2508–2516.
114.
VergheseJLeValleyADerbyC. Leisure activities and the risk of amnestic mild cognitive impairment in the elderly. Neurology. 2006;66(6):821–827.
115.
WilsonRSMendes De LeonCFBarnesLL. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA. 2002;287(6):742–748.
